Quick Answer
CalciMedica, Inc. reported Research And Development Expense of $15.23 million for the year ending 2025.
- CalciMedica, Inc. showed an increase of +5.2% in Research And Development Expense from 2024 to 2025.
- This data is from CalciMedica, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $8.40 million | Q1 2020: $6.09 million | Q2 2020: $4.63 million | Q3 2020: $4.76 million | Q1 2021: $6.45 million | Q2 2021: $4.17 million | Q3 2021: $4.02 million | Q1 2022: $2.93 million | Q2 2022: $2.26 million | Q3 2022: $1.24 million | Q1 2023: $6.49 million | Q2 2023: $3.81 million | Q3 2023: $2.77 million | Q1 2024: $2.94 million | Q2 2024: $4.16 million | Q3 2024: $3.55 million | Q1 2025: $4.22 million | Q2 2025: $4.05 million | Q3 2025: $3.85 million.
- Over the full 7 years of available data (2019 to 2025), CalciMedica, Inc.'s Research And Development Expense has declined by 50.2%.
- Historical annual values: Fiscal year 2025: $15.23 million | Fiscal year 2024: $14.48 million | Fiscal year 2023: $15.86 million | Fiscal year 2022: $8.35 million | Fiscal year 2021: $18.90 million | Fiscal year 2020: $20.96 million | Fiscal year 2019: $30.58 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: